The New Standard in Wound Care

VHT-200

Vaporox has designed its next-generation (VHT-200) device and submitted a 510(k) to the FDA. Clearance is anticipated soon.

Pending 510(K), not available for sale within the United States.

I had a chronic DFU that was 6 years old and was preventing me from getting a lifesaving kidney and pancreatic transplant. After 9 weeks of treatment with VHT, my wound closed, and I received my transplant.”

Ken Mitchell

Sacramento, CA

See video of Ken’s Story

The New Standard in Wound Care

VHT-200

Bioventus Acquires Minority Stake in Vaporox

Clinical Study demonstrates VHT heals 82%+ of chronic wounds

Vaporox submits 510(k) to the FDA for its next-generation device

Footer